14. Kenneth Frazier - Merck

Kenneth Frazier
CEO, Merck
Total Compensation: $13.4 million

Professional Profile: Kenneth Frazier, 59, didn't take a traditional path to the CEO's chair. A graduate of Harvard Law School, he started his Merck ($MRK) career in the company's legal department and made his way up to EVP and general counsel. After leading Merck's defense of the Vioxx litigation, he earned a promotion to president of the drugmaker's global human health business. From there, he took the CEO's office in 2011 and stepped into the chairman's role later that year.

Company Profile: It wasn't easy being Merck in 2013. Sales declined 7% to $44 billion, down from 2012's $47.3 billion haul. That hit was primarily thanks to Singulair's patent cliff, though several other products--including osteoporosis med Fosamax and cholesterol drug Vytorin--saw their sales sink as well.

That's not to say there weren't bright spots. Vaccines was one, with HPV jab Gardasil upping sales by 12% and pushing the unit's haul to about $4.8 billion. The company also made advances in the clinic on a closely watched cancer immunotherapy candidate and a highly anticipated hep C combo treatment.

But in the year's last quarter, Merck announced a $2.5 billion global overhaul--its fourth major sweep since 2008. After laying out plans to slash 8,500 jobs from its R&D and commercial operations, the cuts began rolling in; in November alone, Merck announced it would ax 500 jobs in West Point, PA, as well as close two plants in Puerto Rico. -- Carly Helfand (email | Twitter)

For more:
Special Report: 20 Highest-Paid Biopharma CEOs of 2012 - Kenneth Frazier - Merck
Merck CEO says $14B consumer sale is enough dealmaking for now
Merck CEO: We'll decide fate of animal health, consumer biz by year's end
Struggling Merck slashing 8,500 jobs in major R&D, commercial reorganization

14. Kenneth Frazier - Merck
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.